BIACURE THERAPIES, INC.

Medtech · Private

TherawaveTM 100, a high-frequency energy device for treating fungal nail infections without drugs

Grants
$2.3M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Treatment of Onychomycosis Utilizing Targeted, Controlled High-Frequency Energy$250,114
Federal grantDepartment of Health and Human Services · Phase II · Using Targeted, Controlled High Frequency Energy for Treatment of Onychomycosis$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Using Targeted, Controlled High Frequency Energy for Treatment of Onychomycosis$1,000,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2263Mercury Biomed LLC——
2264ORTHOMECHANICA, INC.——
2265Telo Genomics Corp.—$98K
2266BIACURE THERAPIES, INC.——
2267LENA BIOSCIENCES, INC.——
2268Forsagen LLC——
2269NANOINNOVATIONS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.